Democratising clinical genomics while protecting data privacy
1 February 2017 | By Jurgi Camblong (CEO, Sophia Genetics)
Sophia Genetics co-founder and CEO, Jurgi Camblong, tackles issues of privacy and security for healthcare patient data...
List view / Grid view
Articles
Transforming healthcare in the era of Trump: An opportunity to disrupt
20 January 2017 | By Stephen Klasko, President and CEO, Thomas Jefferson University and Jefferson Health; Editor-in-Chief, Healthcare Transformation
With Trump’s rule imminent, President and CEO of Thomas Jefferson University, Stephen Klasko, puts forth a manifesto for healthcare reform, disruption and change…
The Good, the Bad, and the Donald: what Pharma can expect from 2017
11 January 2017 | By Niamh Marriott, Digital Editor
From an orphan drug sales boom to uncharted political landscapes, the CPhI Worldwide expert panel predict pharma’s biggest opportunities and threats in 2017.
Issue #6 2016 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
Raman In-Depth Focus 2016
In this supplement: Raman imaging evaluating counterfeit Cialis® tablets; analysis of capsule-based dry powder inhalers; Raman spectroscopy to authenticate medicines; Raman roundtable; as well as expert views...
Application Notes & Whitepapers 2016
13 December 2016 | By European Pharmaceutical Review
With the huge range of processes involved in drug discovery and manufacture, it's no wonder we had to create a separate magazine for this content – and as such we have a wide variety of applications...
RMMs In-Depth Focus
In this RMMs In-Depth Focus: the role of statistical analysis in validating rapid microbiological methods; considerations when using RMMs for use in pharmaceutical microbiology; & RMMs roundtable...
How Trump’s victory will impact Life Sciences
13 December 2016 | By Alex Pye and Mark Brewer, Life Sciences analysts, finnCap
Threats to immediately end Obamacare? Import cheaper drugs from overseas? Analysts Alex Pye and Mark Brewer look to the facts for Trump's pharma impact...
The existence of life in extreme hostile environments
The beauty of the diversity of organic life stems from the ability of certain organisms to thrive in hostile and extreme climatic and environmental conditions where most normal life systems cannot survive1 . These extraordinary, microscopic forms have the power to persist more strongly than large macroscopic creatures2 . Most…
The prospects of medicinal plants in the treatment of breast cancer
Plants that have known medicinal properties are plentiful in Africa, and primary healthcare in the developing world has, since ancient times, relied heavily on their cultivation and use. Increasingly, too, the uses and effects of medicinal plants are becoming of interest globally.
Quality by Design for generic products: opportunities and challenges
Quality by Design (QbD) precepts provide opportunities for enhancing efficiencies and reducing costs, especially for generic products. Over 80% of prescriptions dispensed in the United States in 2012 utilised generic dosage forms and it is unlikely that this proportion will increase to any extent because fewer innovative drugs are set…
Spray drying – various challenges, one solution?
Spray drying is a proven, flexible and scalable process used within the pharmaceutical industry to address a wide range of formulation and drug delivery challenges. Its versatility has been proven through applications to both small chemical and biopharmaceutical drugs for product delivery via multiple routes of administration.
The changing dynamics of the life sciences landscape
The life sciences industry is dynamic and as we move towards 2020 and beyond, associated technologies will continue to converge. The forthcoming political, socio-economic and scientific era will throw up challenges, however, with these challenges will come great opportunities. As times change, pharmaceutical companies will need to employ innovative strategies…
Do past pension schemes haunt the pharmaceutical industry?
12 December 2016 | By Rosalind Connor, Partner, ARC Pensions Law
Rosalind Connor, a Partner at ARC Pensions Law, warns of the danger of a sustainable R+D industry due to global changes in pension law...
P is for Psoriasis
5 December 2016 | By Niamh Louise Marriott, Digital Editor
P is for Psoriasis - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
